FDA Proved Lansoprazole for Injection of Inhibiting Gastric Acid

FDA Proved Lansoprazole For Injection Of Inhibiting Gastric Acid
 
Lansoprazole  is a proton-pump inhibitor (PPI) which inhibits the stomach's production of gastric acids.
It is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available. It is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and levolansoprazole. Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift.
Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). and the effects of the drug last for over 24 hours after it has been used for a day or more. Lansoprazole, 30-mg administered nasogastrically, effectively controls intragastric pH and is an alternative to intravenous pantoprazole in patients who are unable to swallow solid-dose formulations.

Indications
Lansoprazole is indicated for treatment of:
Ulcers of the stomach and duodenum, and NSAID-induced ulcers
 
Gastroesophageal reflux disease
Zollinger-Ellison syndrome

Side effects
Common: diarrhea, abdominal pain
Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions including (erythroderma Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea. FDA Proved Lansoprazole For Injection Of Inhibiting Gastric Acid
 
Lansoprazole  is a proton-pump inhibitor (PPI) which inhibits the stomach's production of gastric acids.
It is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available. It is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and levolansoprazole. Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift.
Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). and the effects of the drug last for over 24 hours after it has been used for a day or more. Lansoprazole, 30-mg administered nasogastrically, effectively controls intragastric pH and is an alternative to intravenous pantoprazole in patients who are unable to swallow solid-dose formulations.

Indications
Lansoprazole is indicated for treatment of:
Ulcers of the stomach and duodenum, and NSAID-induced ulcers
 
Gastroesophageal reflux disease
Zollinger-Ellison syndrome

Side effects
Common: diarrhea, abdominal pain
Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions including (erythroderma Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea.

Pelvic External Fixation

There are two kinds of external fixations for pelvic fractures, namely temporary fixation and therapeutic fixation.

Temporary fixation depends on on-site assistance. Assuming that the patient has serious open injury, severe hemorrhagic shock, and serious fracture dislocation, the rescue personnel will provide temporary external fixation support to maintain the stability of the pelvis, reduce secondary injuries, and correct the continuous aggravation of hemorrhagic loss on the scene. The therapeutic external fixation stent is used to correct the dislocation of the fracture through routine examination after admission, evaluation of the injury, and external fixation installation through treatment, maintain the relative stability of the fracture, create a very quiet environment for the fracture healing, and lay the foundation for the healing of the fracture. External fixation is an important method for pelvic fractures.

Pelvic External Fixation,pelvic ex fix,Pelvic External Fixator,pelvic fixator

Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.medthofixation.com